AZN Astrazeneca plc

  1. Stocks
  2. Healthcare
  3. NYSE: AZN

Price (delayed)

$165.98

Market cap

$257.27B

P/E Ratio

24.63

Dividend/share

$3.21

EPS

$6.74

Enterprise value

$284.62B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 23
Relative Valuation: Rel. Valuation: 56
Relative Profitability: Rel. Profitability: 94

AstraZeneca (LSE/STO/Nasdaq: AZN ) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal ...

Highlights
AZN's price to earnings (P/E) is 80% lower than its 5-year quarterly average of 120.4 and 11% lower than its last 4 quarters average of 27.7
Astrazeneca's EPS has increased by 26% YoY
The quick ratio has declined by 8% since the previous quarter and by 3% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.astrazeneca.com
Peers: PFE BMY MRK JNJ

Key stats

What are the main financial stats of AZN

AZN stock price

How has the Astrazeneca stock price performed over time
Intraday
0.91%
1 week
6.09%
1 month
-1.98%
1 year
3.14%
YTD
-9.72%
QTD
-12.47%

Financial performance

How have Astrazeneca's revenue and profit performed over time
Revenue
$61.37B
Gross profit
$50.25B
Operating income
$13.97B
Net income
$10.45B
Gross margin
81.9%
Net margin
17%
AZN's net income is up by 26% year-on-year
AZN's operating income is up by 23% year-on-year but it is down by 2.4% since the previous quarter
AZN's net margin is up by 16% year-on-year
The operating margin has grown by 14% YoY but it has contracted by 3.8% from the previous quarter

Price vs fundamentals

How does AZN's price correlate with its fundamentals

Growth

What is Astrazeneca's growth rate over time

Valuation

What is Astrazeneca stock price valuation
AZN P/E details
P/E
24.63
P/B
5.11
P/S
4.2
EV/EBIT
19.88
EV/EBITDA
13.77
EV/Sales
4.64
AZN's price to earnings (P/E) is 80% lower than its 5-year quarterly average of 120.4 and 11% lower than its last 4 quarters average of 27.7
Astrazeneca's EPS has increased by 26% YoY
The stock's price to book (P/B) is 12% less than its last 4 quarters average of 5.8 and 7% less than its 5-year quarterly average of 5.5
AZN's equity is up by 12% year-on-year and by 6% since the previous quarter
The stock's price to sales (P/S) is 11% less than its last 4 quarters average of 4.7 and 9% less than its 5-year quarterly average of 4.6
Astrazeneca's revenue has increased by 9% YoY

Efficiency

How efficient is Astrazeneca business performance
The return on assets is up by 17% year-on-year
Astrazeneca's return on sales has increased by 13% YoY but it has decreased by 3.7% QoQ
Astrazeneca's return on invested capital has increased by 11% YoY but it has decreased by 6% QoQ
The company's return on equity rose by 10% YoY but it fell by 2.7% QoQ

Dividends

What is AZN's dividend history
Dividend details
DPS
$3.21
Dividend yield
1.94%
Payout ratio
47.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Astrazeneca financials performed over time
The company's total assets is 77% higher than its total liabilities
The quick ratio has declined by 8% since the previous quarter and by 3% year-on-year
AZN's current ratio is up by 3.5% YoY but it is down by 2.2% from the previous quarter
AZN's debt is 36% smaller than its equity
AZN's debt to equity is down by 12% year-on-year and by 11% since the previous quarter
AZN's equity is up by 12% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.